Jose Urquidez, MD
Physical Medicine & Rehabilitation · Austin, TXNPI 1053357871
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $269,123 of the $331,904 with a category attached, or 81.1%. Ipsen Biopharmaceuticals, Inc accounts for 78.6% of it on its own, with 21 other manufacturers making up the rest. Among physical medicine & rehabilitation clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 522 payments — averaging $635.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ipsen Biopharmaceuticals, Inc$261K
- Medtronic$29K
- Merz North America, Inc.$15K
- Piramal Critical Care$13K
- Merz Pharmaceuticals, LLC$9K
- Microtransponder, Inc.$2K
- plus $3K from 16 others
What the payments were for
- Consulting fees$9,5233%
- Speaking & faculty fees$269,12381%
- Travel & lodging$37,45911%
- Food & beverage$15,5905%
- Gifts$2100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ipsen Biopharmaceuticals, Inc | 211 | $260,967 |
| Medtronic(2 entities) | 100 | $29,288 |
| Merz North America, Inc. | 24 | $15,028 |
| Piramal Critical Care | 16 | $12,575 |
| Merz Pharmaceuticals, LLC | 55 | $9,375 |
| Microtransponder, Inc. | 7 | $1,985 |
| AbbVie(2 entities) | 45 | $672 |
| Amneal Pharmaceuticals LLC | 3 | $498 |
| Saol Therapeutics Inc. | 15 | $436 |
| Lundbeck LLC | 5 | $193 |
| Revance Therapeutics, Inc. | 3 | $175 |
| Lilly USA, LLC | 8 | $144 |
| Teva Pharmaceuticals USA, Inc. | 6 | $126 |
| Upsher-smith Laboratories LLC | 6 | $102 |
| Jazz Pharmaceuticals Inc. | 4 | $74 |
| Tersera Therapeutics LLC | 4 | $62 |
| Biohaven Pharmaceuticals, Inc. | 3 | $50 |
| Axsome Therapeutics, Inc. | 1 | $45 |
| Acorda Therapeutics, Inc | 2 | $42 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $31 |
| Coloplast | 1 | $24 |
| Metacel Pharmaceuticals LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DYSPORT$258,201
- GABLOFEN$49,911
- XEOMIN$23,301
- LIORESAL$13,358
- SYNCHROMEDII$8,292
- SYNCHROMED$5,253
- LYVISPAH$450
- ASCENDA$101
How this compares
$331,904 in reported general payments places this provider in the 95th percentile of 651 physical medicine & rehabilitation providers in Texas.
See all physical medicine & rehabilitation providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BotoxOnabotulinumtoxina | 33 | $62,706 |
| AmpyraDalfampridine | 11 | $46,033 |
| Nurtec OdtRimegepant Sulfate | 20 | $24,902 |
| DysportAbobotulinumtoxina | 19 | $23,821 |
| Baclofen | 122 | $2,864 |
| Lidocaine | 13 | $2,048 |
| Gabapentin | 122 | $1,437 |
| Modafinil | 18 | $1,421 |
| Diazepam | 66 | $778 |
| Temazepam | 14 | $673 |
| Alprazolam | 13 | $605 |
| Tizanidine Hcl | 19 | $518 |
| Methylphenidate Hcl | 11 | $245 |
| Pregabalin | 11 | $224 |
| Duloxetine Hcl | 23 | $213 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieBotox | $672 | $62,70633 claims |
| Acorda Therapeutics, IncAmpyra | $42 | $46,03311 claims |
| Ipsen Biopharmaceuticals, IncDysport | $260,967 | $23,82119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 651 physical medicine & rehabilitation providers in Texas.
Other physical medicine & rehabilitation in Austin
- Joseph OwensAustin$9K
- Vishal KancherlaAustin$5K
- Anand JoshiAustin$4K
- Lisa PersynAustin$3K
- Gerard FranciscoHouston$364K
- Gireesh ShardaDallas$172K
- Suzanne ManziHouston$143K
- Cindy IvanhoeHouston$111K
- Chad McNeilTyler$64K
- Sheng LiHouston$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.